Earnings summaries and quarterly performance for Amneal Pharmaceuticals.
Executive leadership at Amneal Pharmaceuticals.
Chintu Patel
Detailed
Co-Chief Executive Officer
CEO
Chirag Patel
Detailed
Co-Chief Executive Officer and President
CEO
AK
Anastasios Konidaris
Detailed
Executive Vice President, Chief Financial Officer
AB
Andrew Boyer
Detailed
Executive Vice President, Chief Commercial Officer-Generics
JD
Jason Daly
Detailed
Executive Vice President, Chief Legal Officer and Corporate Secretary
NS
Nikita Shah
Detailed
Executive Vice President, Chief Human Resources Officer
Board of directors at Amneal Pharmaceuticals.
Research analysts who have asked questions during Amneal Pharmaceuticals earnings calls.
David Amsellem
Piper Sandler Companies
6 questions for AMRX
Also covers: ABBV, ALKS, AMGN +27 more
LS
Leszek Sulewski
Truist Securities
5 questions for AMRX
Also covers: AKBA, ANIP, BHC +6 more
CS
Christopher Schott
JPMorgan Chase & Co.
3 questions for AMRX
Also covers: ABBV, AMGN, BIIB +15 more
BP
Balaji Prasad
Barclays
2 questions for AMRX
Also covers: ALVO, ELAN, LGND +7 more
CS
Chris Schott
JPMorgan Chase & Company
2 questions for AMRX
Also covers: ABBV, AMGN, BIIB +11 more
MD
Matt Dellatorre
Goldman Sachs
2 questions for AMRX
Also covers: VTRS
CS
Chris Stott
JPMorgan Chase & Co.
1 question for AMRX
LS
Les Sulewski
Truist
1 question for AMRX
Also covers: BHC, CRMD, PCRX +2 more
MD
Matthew Dellatorre
Goldman Sachs Group Inc.
1 question for AMRX
Also covers: INCY, TEVA
Recent press releases and 8-K filings for AMRX.
Amneal Pharmaceuticals Reports Strong 2025 Results and Provides 2026 Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals reported a defining year of excellence in 2025, with full-year revenue growing 8% to $3 billion, adjusted EBITDA increasing 10% to $688 million, and adjusted EPS rising 43% to $0.83. The company also reduced net leverage to 3.5 times by year-end 2025.
- For 2026, the company provided guidance expecting total company revenue between $3.05 billion-$3.15 billion (up 1%-4%), adjusted EBITDA between $720 million-$760 million (up 5%-10%), and adjusted EPS between $0.93-$1.03 (reflecting 12%-24% earnings growth).
- The company saw strong performance from its specialty segment, with Trexall reaching 3% market share and 23,000 patients on therapy one year post-launch, and expects to double its market share in 2026. New product launches in Q4 2025 included Brekiya, an auto-injector for severe migraine and cluster headache patients.
- Amneal is expanding its portfolio with significant progress in biosimilars, having received approval for its fourth and fifth products in December, and is on track to have 6 biosimilars in the U.S. market by 2027, including biosimilar Xolair which is expected to be a major opportunity. The company also highlighted its collaboration with Pfizer on GLP-1s, with manufacturing build-out on target.
4 days ago
Amneal Pharmaceuticals Announces Q4 and Full Year 2025 Results and Provides 2026 Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals reported strong Q4 2025 results with revenue of $814 million (+11%), adjusted EBITDA of $175 million (+13%), and adjusted EPS of $0.21 (+75%), contributing to full-year 2025 revenue of $3.02 billion (+8%), adjusted EBITDA of $688 million (+10%), and adjusted EPS of $0.83 (+43%).
- The company provided FY 2026 guidance, projecting revenue between $3.05 billion and $3.15 billion (+1% to +4% growth), adjusted EBITDA between $720 million and $760 million (+5% to +10% growth), and adjusted EPS between $0.93 and $1.03 (+12% to +24% growth).
- Growth was driven by the Specialty segment, which grew 19% in FY 2025, with continued robust uptake of CREXONT® and the successful Q4 2025 launch of Brekiya® DHE autoinjector, which generated $1.6 million in its first quarter.
- Amneal successfully refinanced its debt in July 2025, reducing interest costs and extending maturities to 2032, resulting in a net leverage of 3.5x at the end of 2025, down from 3.9x at the end of 2024.
4 days ago
Amneal Pharmaceuticals Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals reported strong Q4 2025 revenue of $814 million, up 11%, and full-year 2025 revenue of $3 billion, up 8%, with adjusted EBITDA growing 13% to $175 million in Q4 and 10% to $688 million for the full year.
- The company issued 2026 guidance, projecting total revenue between $3.05 billion and $3.15 billion (up 1%-4%), adjusted EBITDA between $720 million and $760 million (up 5%-10%), and adjusted EPS between $0.93 and $1.03 (up 12%-20%).
- Strategic product highlights include CREXONT, which achieved 3% market share with 23,000 patients one year post-launch and is expected to double its market share to over 6% in 2026. The company also launched Brekiya in Q4 2025, with anticipated peak sales of $50 million-$100 million.
- Amneal improved its financial position by reducing net leverage to 3.5x at the end of 2025 and refinancing debt to extend maturities to 2032 and lower interest expenses.
4 days ago
Amneal Pharmaceuticals Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals reported a strong financial performance in 2025, with revenue growing 8% to $3 billion, adjusted EBITDA increasing 10% to $688 million, and adjusted EPS rising 43% to $0.83. The company also reduced its net leverage to 3.5x by year-end.
- For 2026, the company expects continued growth, with total revenue projected between $3.05 billion and $3.15 billion (up 1%-4%), adjusted EBITDA between $720 million and $760 million (up 5%-10%), and adjusted EPS between $0.93 and $1.03 (up 12%-24%).
- Growth is anticipated to be driven by the Affordable Medicines segment, which is expected to accelerate 7%-8% in 2026 due to new complex product launches. The Specialty segment saw Q4 2025 revenue growth of 38%, with Trexall achieving 3% market share and projected peak U.S. sales of $300 million-$500 million.
- Strategic initiatives include a progressing GLP-1 collaboration with Pfizer and building a long-term growth engine in biosimilars, aiming for 6 biosimilars in the U.S. market by 2027. The company was also added to the S&P SmallCap 600 index.
4 days ago
Amneal Pharmaceuticals, Inc. Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Guidance
AMRX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Amneal Pharmaceuticals, Inc. (AMRX) reported Q4 2025 net revenue of $814 million, an 11% increase compared to Q4 2024, with diluted income per share of $0.11 and adjusted diluted EPS of $0.21.
- For the full year 2025, the company achieved net revenue of $3.02 billion, an 8% increase from 2024, with diluted income per share of $0.22 and adjusted diluted EPS of $0.83.
- The company provided 2026 financial guidance, projecting net revenue between $3.05 billion and $3.15 billion, Adjusted EBITDA between $720 million and $760 million, and Adjusted Diluted EPS between $0.93 and $1.03.
- Specialty net revenue increased 38% in Q4 2025, driven by CREXONT® and UNITHROID®, while for the full year 2025, Specialty grew 19%, Affordable Medicines grew 4%, and AvKARE grew 12%.
4 days ago
Amneal Pharmaceuticals Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals reported net revenue of $814 million for the fourth quarter of 2025, an 11% increase compared to the fourth quarter of 2024, with Adjusted Diluted EPS of $0.21.
- For the full year 2025, net revenue reached $3.02 billion, an 8% increase from 2024, and Adjusted Diluted EPS was $0.83.
- The company's Specialty net revenue increased 19% in 2025, driven by strong uptake of CREXONT® and the launch of the BREKIYA® autoinjector.
- Amneal provided 2026 financial guidance, projecting net revenue between $3.05 billion and $3.15 billion, Adjusted EBITDA of $720 million to $760 million, and Adjusted Diluted EPS of $0.93 to $1.03.
4 days ago
Amneal Pharmaceuticals Amends Term Loan Credit Agreement
AMRX
Debt Issuance
- Amneal Pharmaceuticals LLC entered into Amendment No. 2 to Term Loan Credit Agreement on February 2, 2026, with lenders including JPMorgan Chase Bank, N.A. as administrative agent.
- The company anticipates estimated savings related to the entry into this Repricing Amendment.
Feb 2, 2026, 11:36 PM
Amneal Provides 2025 Guidance and Highlights Strategic Growth Drivers
AMRX
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Amneal projects Full Year 2025 Net Revenues of $3.0 - $3.1 billion, Adjusted EBITDA of $675M - $685M, and Operating Cash Flow of $300M - $330M.
- The company has significantly reduced its Net Leverage from 7.4x in 2019 to 3.7x in 2025.
- Amneal is driving long-term growth through a diversified portfolio, including Specialty Branded products, an expanding Biosimilars portfolio with six expected by 2027, and a strategic collaboration in the GLP-1/Peptides space.
- A significant new product launch phase in Affordable Medicines is underway, with key launches such as Lenalidomide (Revlimid®) in Q1 2026 and Denosumab biosimilars (PROLIA® & XGEVA®) in Q4 2025.
Jan 14, 2026, 12:30 AM
Amneal Pharmaceuticals Presents Growth Strategy and 2026 Financial Outlook at J.P. Morgan Healthcare Conference
AMRX
Guidance Update
Product Launch
New Projects/Investments
- Amneal Pharmaceuticals is undergoing a transformation, with 70%-75% of the complex generics shift complete, and a future focus on biosimilars and specialty branded products, aiming to be the number one affordable medicines company in America by 2030.
- The company's specialty branded product, Crexont, is performing strongly, with 22,000 patients and 3.2% market share currently, projected to reach 6% market share in 2026 and generate over $120 million in revenue for 2026, with peak sales estimated between $300 million and $500 million.
- Amneal is expanding its biosimilar portfolio, with five biosimilars launched or about to launch, including two Denosumab presentations (Xgeva and Prolia), and an Xolair biosimilar expected for early 2027. The company aims to be a top three biosimilar player and plans vertical integration in 2026.
- For 2026, Amneal anticipates EBITDA to grow faster than revenue and projects a double-digit EPS growth rate, specifically 20%-25%+, driven by reduced interest expenses. The company also expects a 50-60 basis points improvement in gross margin.
- Capital deployment priorities include biosimilars first, followed by branded assets in Parkinson's or oncology, with a disciplined approach to maintain net leverage just below three times.
Jan 14, 2026, 12:30 AM
Amneal Outlines Strategic Shift to Complex Generics, Biosimilars, and Specialty Products, Projects Double-Digit EPS Growth in 2026
AMRX
New Projects/Investments
Guidance Update
Product Launch
- Amneal is undergoing a strategic transformation, shifting its focus from traditional retail generics to complex generics, biosimilars, and specialty branded products, with only 25% of revenue now from retail oral solid generics.
- The company reported strong financial progress, having doubled revenue and EBITDA over the last six years and reducing net leverage from 7.4 to 3.7.
- For 2026, Amneal anticipates high single-digit growth in its affordable medicines segment, a 50-60 basis points improvement in gross margin, and double-digit EPS growth.
- Key product highlights include the successful launch of Crexont, a Parkinson's treatment, which is projected to generate over $120 million in revenue in 2026 and achieve 6% market share.
- Amneal is heavily investing in biosimilars, aiming to become a top three player and vertically integrate, and has a significant partnership with Pfizer for GLP-1 peptide manufacturing.
Jan 14, 2026, 12:30 AM
Quarterly earnings call transcripts for Amneal Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more